
  
    
      
        Background_NNP
        Cancer_NNP is_VBZ a_DT progressive_JJ genetic_JJ disease_NN that_WDT involves_VBZ
        the_DT accumulation_NN of_IN multiple_JJ and_CC heterogeneous_JJ genetic_JJ and_CC
        epigenetic_JJ changes_NNS ._. Among_IN the_DT 30_CD ,_, 000_CD -_: 40_CD ,_, 000_CD human_JJ genes_NNS [_NN
        1_CD 2_CD ]_NN ,_, an_DT expanding_VBG list_NN of_IN genes_NNS has_VBZ been_VBN shown_VBN to_TO be_VB
        involved_VBN in_IN cancer_NN development_NN and_CC progression_NN ._. Recently_RB
        developed_VBN technologies_NNS ,_, including_VBG cDNA_NN microarrays_NNS ,_, allow_VB
        cancer_NN researchers_NNS to_TO screen_VB thousands_NNS of_IN genes_NNS
        simultaneously_RB to_TO identify_VB genes_NNS that_WDT show_NN abnormal_JJ
        expression_NN in_IN cancers_NNS [_NN 3_CD 4_CD 5_CD 6_CD ]_NN ._.
        Cancer_NN researchers_NNS face_VBP a_DT serious_JJ challenge_NN when_WRB trying_VBG
        to_TO apply_VB these_DT tools_NNS to_TO clinical_JJ cancer_NN specimens_NNS ._. First_LS ,_,
        cancers_NNS are_VBP often_RB detected_VBN at_IN a_DT late_JJ stage_NN in_IN development_NN ,_,
        after_IN multiple_JJ genetic_JJ and_CC epigenetic_JJ changes_NNS have_VBP rendered_VBN
        the_DT cancer_NN metastatic_JJ and_CC highly_RB refractory_JJ even_RB to_TO harsh_JJ
        treatment_NN ._. Multiple_NNP clones_NNS in_IN the_DT same_JJ tumor_NN mass_NN ,_, which_WDT
        can_MD often_RB be_VB distinguished_VBN by_IN morphological_JJ features_NNS ,_, would_MD
        yield_VB more_JJR information_NN if_IN they_PRP could_MD be_VB microdissected_JJ and_CC
        analyzed_VBD separately_RB ._. Second_JJ ,_, tumor_NN tissues_NNS invariably_RB
        include_VBP a_DT mixture_NN of_IN different_JJ cells_NNS ,_, such_JJ as_IN inflammatory_JJ
        cells_NNS ,_, stromal_NN cells_NNS ,_, vascular_NN cells_NNS ,_, and_CC others_NNS ._. Each_DT type_NN
        of_IN cells_NNS may_MD contribute_VB to_TO a_DT unique_JJ aspect_NN of_IN the_DT cancer_NN
        phenotype_NN and_CC may_MD serve_VB as_IN a_DT target_NN for_IN treatment_NN ._.
        Therefore_RB ,_, there_EX is_VBZ a_DT need_NN to_TO dissect_NN those_DT cells_NNS for_IN
        separate_JJ study_NN ._. For_IN example_NN ,_, it_PRP was_VBD found_VBN that_DT tumor_NN
        vascular_NN cells_NNS have_VBP distinct_JJ gene_NN expression_NN profiles_NNS from_IN
        those_DT of_IN normal_JJ vascular_NN cells_NNS [_NN 7_CD ]_NN ,_, and_CC the_DT genes_NNS that_WDT
        are_VBP uniquely_RB expressed_VBN on_IN the_DT surface_NN of_IN tumor_NN endothelium_NN
        cells_NNS can_MD serve_VB as_IN targets_NNS for_IN specific_JJ cancer_NN therapy_NN ._.
        Finally_RB ,_, a_DT key_JJ breakthrough_NN in_IN cancer_NN treatment_NN would_MD come_VB
        from_IN early_JJ detection_NN and_CC diagnosis_NN of_IN cancer_NN and_CC the_DT study_NN
        of_IN molecular_JJ events_NNS in_IN the_DT early_JJ stages_NNS of_IN cancer_NN
        progression_NN ._. A_DT difficulty_NN in_IN studying_VBG cancer_NN at_IN early_JJ
        stages_NNS is_VBZ that_IN the_DT tumor_NN size_NN is_VBZ small_JJ and_CC only_RB limited_JJ
        material_NN can_MD be_VB obtained_VBN through_IN means_VBZ such_JJ as_IN fine_NN needle_NN
        aspiration_NN ._. Identification_NNP of_IN the_DT genetic_JJ changes_NNS in_IN such_JJ a_DT
        small_JJ sample_NN is_VBZ especially_RB challenging_VBG because_IN only_RB limited_JJ
        assays_NNS can_MD be_VB performed_VBN using_VBG conventional_JJ approaches_NNS ._. It_PRP
        is_VBZ obvious_JJ that_IN the_DT full_JJ potential_NN of_IN genomic_JJ technologies_NNS
        will_MD only_RB be_VB realized_VBN if_IN they_PRP can_MD be_VB applied_VBN to_TO minute_NN
        amounts_NNS of_IN biological_JJ material_NN ._.
        For_IN a_DT typical_JJ gene_NN expression_NN profiling_VBG experiment_NN
        carried_VBD out_IN on_IN a_DT glass_NN microarray_NN where_WRB thousands_NNS of_IN cDNA_NN
        probes_NNS are_VBP deposited_VBN in_IN an_DT orderly_JJ manner_NN ,_, RNA_NNP is_VBZ first_RB
        isolated_VBN from_IN the_DT biological_JJ material_NN under_IN study_NN ._. The_DT mRNA_NN
        (_( 1_CD -_: 5_CD %_NN of_IN total_JJ RNA_NNP )_) is_VBZ reverse_JJ transcribed_JJ to_TO cDNA_NN ,_, during_IN
        which_WDT process_VBP fluorescent_NN dyes_NNS (_( Cy_NNP 3_CD or_CC Cy_NNP 5_LS )_) are_VBP
        incorporated_VBN ._. The_DT labeled_VBN cDNAs_NNS are_VBP hybridized_JJ to_TO the_DT
        microarray_NN and_CC ,_, after_IN washing_VBG ,_, the_DT fluorescent_NN signals_NNS are_VBP
        detected_VBN by_IN a_DT laser_NN scanner_NN ._. Current_JJ protocols_NNS typically_RB
        require_VBP more_JJR than_IN 50_CD μg_NN of_IN total_JJ RNA_NNP for_IN consistent_JJ
        microarray_NN hybridization_NN ._. Several_JJ hundred_CD milligrams_NNS of_IN
        tumor_NN tissues_NNS are_VBP often_RB needed_VBN to_TO obtain_VB this_DT much_JJ RNA_NNP ,_,
        which_WDT is_VBZ simply_RB unavailable_JJ in_IN many_JJ situations_NNS ._. Thus_RB ,_, it_PRP is_VBZ
        crucial_JJ to_TO develop_VB a_DT more_RBR sensitive_JJ and_CC reliable_JJ procedure_NN
        that_WDT requires_VBZ less_JJR RNA_NNP ._. Several_JJ molecular_JJ biology_NN
        approaches_NNS ,_, such_JJ as_IN T_NN 7_CD in_IN vitro_NN transcription_NN and_CC PCR_NNP based_VBD
        assays_NNS ,_, have_VBP been_VBN attempted_VBN [_NN 8_CD 9_CD 10_CD ]_NN ._. However_RB ,_, only_RB
        cursory_NN analysis_NN has_VBZ been_VBN carried_VBN out_IN to_TO validate_NN the_DT
        assays_NNS ,_, and_CC limited_JJ confirmation_NN experiments_NNS have_VBP been_VBN
        performed_VBN to_TO evaluate_VB the_DT validity_NN of_IN the_DT amplification_NN
        results_NNS ._.
        In_IN this_DT study_NN ,_, we_PRP performed_VBD and_CC analyzed_VBN a_DT set_NN of_IN nine_CD
        microarray_NN experiments_NNS to_TO evaluate_VB an_DT amplification_NN
        protocol_NN adopted_VBN from_IN Wang_NNP 
        et_CC al_NN [_NN 9_CD ]_NN ._. Focusing_VBG primarily_RB on_IN
        the_DT ability_NN to_TO identify_VB differentially_RB expressed_VBD genes_NNS ,_, we_PRP
        developed_VBD the_DT following_VBG criteria_NNS for_IN a_DT successful_JJ
        amplification_NN protocol_NN :_:
        1_LS ._. Because_IN amplification_NN may_MD enhance_VB the_DT signal_NN of_IN genes_NNS
        expressed_VBD at_IN low_JJ copy_NN numbers_NNS ,_, more_JJR genes_NNS should_MD be_VB
        detected_VBN by_IN an_DT amplification_NN protocol_NN than_IN by_IN a_DT regular_JJ
        protocol_NN ._.
        2_LS ._. Most_JJS genes_NNS detected_VBD as_RB differentially_RB expressed_VBD using_VBG
        a_DT regular_JJ protocol_NN should_MD also_RB be_VB detected_VBN using_VBG an_DT
        amplification_NN protocol_NN ._. In_IN other_JJ words_NNS ,_, the_DT two_CD protocols_NNS
        should_MD reveal_VB similar_JJ patterns_NNS of_IN differential_NN
        expression_NN ._.
        3_LS ._. An_DT amplification_NN protocol_NN should_MD generate_VB signal_NN
        intensity_NN profiles_NNS as_RB reproducibly_RB and_CC reliably_RB as_IN a_DT
        regular_JJ protocol_NN ._.
        4_LS ._. Microarray_NNP results_NNS obtained_VBN from_IN an_DT amplification_NN
        protocol_NN should_MD match_VB data_NNS obtained_VBN from_IN other_JJ molecular_JJ
        biology_NN approaches_NNS such_JJ as_IN northern_JJ blotting_VBG ,_, western_JJ
        blotting_VBG and_CC immunohistochemistry_NN assay_NN ._.
        Our_PRP$ results_NNS showed_VBD that_IN our_PRP$ amplification_NN protocol_NN
        produced_VBD reproducible_JJ ,_, reliable_JJ microarray_NN data_NNS that_WDT was_VBD
        consistent_JJ with_IN the_DT regular_JJ protocol_NN ._. We_PRP also_RB confirmed_VBD
        that_IN our_PRP$ amplification_NN protocol_NN revealed_VBD accurate_JJ
        information_NN about_IN the_DT differential_NN expression_NN of_IN low_JJ copy_NN
        number_NN genes_NNS that_WDT failed_VBD to_TO give_VB sufficient_JJ signal_NN
        intensities_NNS using_VBG the_DT regular_JJ protocol_NN ._. Therefore_RB ,_, many_JJ
        clinical_JJ experiments_NNS for_IN which_WDT only_RB a_DT minute_NN amount_NN of_IN
        material_NN is_VBZ available_JJ can_MD be_VB pursued_VBN using_VBG this_DT
        protocol_NN ._.
      
      
        Results_NNS
        
          Enhancement_NNP of_IN signal_NN intensity_NN for_IN genes_NNS expressed_VBD
          at_IN a_DT low_JJ copy_NN number_NN
          We_PRP expected_VBD the_DT amplification_NN protocol_NN to_TO increase_VB the_DT
          signal_NN intensity_NN of_IN low_JJ expressing_VBG genes_NNS ;_: in_IN other_JJ words_NNS ,_,
          the_DT number_NN of_IN genes_NNS having_VBG measurable_JJ signal_NN intensity_NN
          above_IN background_NN levels_NNS from_IN using_VBG the_DT amplification_NN
          protocol_NN should_MD be_VB higher_JJR than_IN that_DT using_VBG the_DT regular_JJ
          protocol_NN ._. We_PRP used_VBD S_NNP /_NN N_NNP >_NN 2_CD ._. 0_CD to_TO determine_VB if_IN a_DT gene_NN has_VBZ
          measurable_JJ signal_NN intensity_NN on_IN an_DT array_NN ;_: i_NNP ._. e_SYM ._. ,_, if_IN the_DT
          difference_NN between_IN signal_NN intensity_NN and_CC background_NN
          intensity_NN is_VBZ greater_JJR than_IN 2_CD ._. 0_CD SD_NNP of_IN the_DT local_JJ background_NN ,_,
          then_RB the_DT gene_NN gives_VBZ adequate_JJ signal_NN intensity_NN ._. We_PRP
          assessed_VBD all_DT 9_CD arrays_NNS ;_: the_DT results_NNS are_VBP summarized_VBD in_IN
          Table_NNP 2_CD ._. The_DT results_NNS showed_VBD that_IN the_DT number_NN of_IN genes_NNS
          whose_WP$ S_NNP /_NN N_NNP ratio_NN exceeds_VBZ 2_CD SD_NNP of_IN background_NN is_VBZ
          consistently_RB higher_JJR in_IN both_DT channels_NNS when_WRB using_VBG the_DT
          amplification_NN protocol_NN ._. The_DT signal_NN intensities_NNS of_IN low_JJ
          expressors_NNS ,_, indeed_RB ,_, are_VBP improved_VBN so_IN that_IN more_JJR genes_NNS
          turned_VBD out_IN to_TO be_VB detectable_JJ ._. Our_PRP$ result_NN also_RB showed_VBD that_IN
          the_DT PCR_NNP step_NN (_( 1_CD or_CC 3_CD cycles_NNS )_) before_IN aRNA_NN amplification_NN
          had_VBD no_DT detectable_JJ effect_NN on_IN the_DT final_JJ results_NNS ._.
        
        
          Consistent_NNP patterns_NNS of_IN differential_NN gene_NN
          expression_NN
          Finding_VBG differentially_RB expressed_VBD genes_NNS is_VBZ one_CD of_IN the_DT
          goals_NNS of_IN microarray_NN technology_NN ._. Ideally_RB ,_, both_DT the_DT regular_JJ
          and_CC amplification_NN protocols_NNS would_MD identify_VB the_DT same_JJ list_NN
          of_IN differentially_RB expressed_VBD genes_NNS ._. We_PRP did_VBD not_RB expect_VB to_TO
          see_VB identical_JJ lists_NNS of_IN differentially_RB expressed_VBD genes_NNS
          generated_VBN from_IN the_DT two_CD protocols_NNS ,_, since_IN we_PRP may_MD not_RB even_RB
          achieve_VB that_DT goal_NN using_VBG the_DT same_JJ protocol_NN twice_RB due_JJ to_TO
          the_DT variability_NN associated_VBN with_IN microarray_NN experiments_NNS [_NN
          12_CD 13_CD 14_CD ]_NN ._. However_RB ,_, we_PRP do_VBP want_VBP to_TO see_VB most_RBS
          differentially_RB expressed_VBD genes_NNS appearing_VBG on_IN both_DT
          lists_NNS ._.
          To_TO identify_VB differentially_RB expressed_VBD genes_NNS ,_, we_PRP
          computed_JJ "_'' smooth_JJ t-statistics_JJ "_'' ._. To_TO apply_VB this_DT method_NN ,_, we_PRP
          first_JJ computed_JJ the_DT mean_NN log_NN intensity_NN and_CC the_DT standard_JJ
          deviation_NN for_IN the_DT replicated_VBN spots_NNS within_IN each_DT channel_NN ._.
          Since_IN the_DT standard_JJ deviation_NN varies_VBZ systematically_RB with_IN
          the_DT mean_NN ,_, we_PRP then_RB fit_VBP a_DT smooth_JJ curve_NN representing_VBG the_DT
          standard_JJ deviation_NN as_IN a_DT function_NN of_IN the_DT mean_NN ._. After_IN
          pooling_VBG the_DT smooth_JJ estimates_NNS of_IN standard_JJ deviation_NN from_IN
          the_DT two_CD channels_NNS ,_, we_PRP used_VBD the_DT pooled_VBN estimates_NNS to_TO compute_VB
          a_DT t-statistic_JJ for_IN each_DT gene_NN [_NN 13_CD 15_CD ]_NN ._. These_DT "_'' smooth_JJ
          t-statistics_JJ "_'' can_MD also_RB be_VB viewed_VBN as_IN "_'' studentized_JJ log_NN
          ratios_NNS "_'' ;_: i_NNP ._. e_SYM ._. ,_, as_IN log_NN ratios_NNS between_IN channels_NNS that_WDT have_VBP
          been_VBN rescaled_JJ to_TO account_VB for_IN the_DT intrinsic_JJ
          variability_NN ._.
          We_PRP found_VBD that_IN the_DT consistency_NN and_CC reproducibility_NN of_IN
          smooth_JJ t-statistics_JJ between_IN experiments_NNS is_VBZ high_JJ
          regardless_RB of_IN the_DT protocol_NN being_VBG used_VBN ._. We_PRP quantified_VBN the_DT
          reproducibility_NN using_VBG the_DT concordance_NN coefficient_NN ,_, which_WDT
          is_VBZ analogous_JJ to_TO the_DT correlation_NN coefficient_NN but_CC measures_NNS
          how_WRB well_RB a_DT set_NN of_IN points_NNS matches_VBZ the_DT identity_NN line_NN [_NN 16_CD
          17_CD 18_CD ]_NN ._. The_DT concordance_NN between_IN experiments_NNS using_VBG the_DT
          regular_JJ protocol_NN ranged_VBD from_IN 0_CD ._. 574_CD to_TO 0_CD ._. 835_CD ,_, with_IN a_DT
          median_NN of_IN 0_CD ._. 739_CD ._. The_DT concordance_NN using_VBG the_DT amplification_NN
          protocol_NN ranged_VBD from_IN 0_CD ._. 843_CD to_TO 0_CD ._. 894_CD ,_, with_IN a_DT median_NN of_IN
          0_CD ._. 873_CD ._. The_DT concordance_NN between_IN the_DT experiments_NNS using_VBG
          different_JJ protocols_NNS ranged_VBD from_IN 0_CD ._. 562_CD to_TO 0_CD ._. 796_CD ,_, with_IN a_DT
          median_NN of_IN 0_CD ._. 652_CD ._.
          Using_VBG data_NNS from_IN all_DT experiments_NNS performed_VBN with_IN the_DT
          regular_JJ protocol_NN ,_, we_PRP computed_JJ a_DT combined_VBN set_NN of_IN smooth_JJ
          t-statistics_JJ ._. We_PRP computed_JJ a_DT similar_JJ set_NN of_IN t-statistics_JJ
          using_VBG data_NNS from_IN all_DT experiments_NNS performed_VBN with_IN the_DT
          amplification_NN protocol_NN ._. Genes_NNP are_VBP viewed_VBN as_RB
          differentially_RB expressed_VBD if_IN the_DT smooth_JJ t-statistic_JJ
          exceeds_VBZ some_DT threshold_NN ;_: for_IN this_DT study_NN ,_, we_PRP chose_VBD genes_NNS
          with_IN smooth_JJ t-statistic_JJ greater_JJR than_IN four_CD in_IN absolute_JJ
          value_NN ._. Using_VBG this_DT criterion_NN ,_, we_PRP found_VBD that_IN the_DT regular_JJ
          protocol_NN identified_VBD 21_CD genes_NNS that_WDT were_VBD differentially_RB
          expressed_VBN between_IN U_NNP 251_CD and_CC LN_NNP 229_CD cell_NN lines_NNS ,_, and_CC the_DT
          amplification_NN protocol_NN identified_VBD 28_CD differentially_RB
          expressed_VBD genes_NNS ._. Fifteen_CD genes_NNS were_VBD common_JJ to_TO both_DT lists_NNS ._.
          Thirteen_CD genes_NNS were_VBD found_VBN using_VBG the_DT amplification_NN
          protocol_NN but_CC not_RB the_DT regular_JJ protocol_NN ;_: the_DT smooth_JJ
          t-statistics_JJ for_IN these_DT genes_NNS ranged_VBD in_IN absolute_JJ value_NN
          from_IN 1_CD ._. 19_CD to_TO 3_CD ._. 96_CD ,_, with_IN a_DT median_NN of_IN 2_CD ._. 23_CD ._. Six_CD genes_NNS were_VBD
          found_VBN using_VBG the_DT regular_JJ protocol_NN but_CC not_RB the_DT
          amplification_NN protocol_NN ;_: the_DT smooth_JJ t-statistics_JJ for_IN these_DT
          genes_NNS using_VBG the_DT amplification_NN protocol_NN ranged_VBD in_IN absolute_JJ
          value_NN from_IN 3_CD ._. 16_CD to_TO 3_CD ._. 97_CD with_IN a_DT median_NN of_IN 3_CD ._. 42_CD ._. In_IN every_DT
          case_NN ,_, the_DT sign_NN of_IN the_DT t-scores_JJ was_VBD the_DT same_JJ using_VBG the_DT
          different_JJ protocols_NNS ,_, indicating_VBG that_IN the_DT same_JJ cell_NN line_NN
          overexpressed_JJ the_DT gene_NN ._.
        
        
          Reproducibility_NNP and_CC reliability_NN of_IN signal_NN
          intensity_NN
          To_TO evaluate_VB whether_IN the_DT amplification_NN protocol_NN
          preserved_VBD signals_NNS that_WDT were_VBD seen_VBN using_VBG the_DT regular_JJ
          protocol_NN ,_, we_PRP first_RB found_VBD all_PDT the_DT spots_NNS in_IN each_DT channel_NN
          (_( U_NNP 251_CD or_CC LN_NNP 229_CD )_) that_IN consistently_RB had_VBD S_NNP /_NN N_NNP >_NN 2_CD ._. 0_CD in_IN all_DT
          five_CD experiments_NNS using_VBG the_DT regular_JJ protocol_NN ._. We_PRP then_RB
          computed_JJ the_DT percentage_NN of_IN those_DT genes_NNS that_WDT also_RB had_VBD S_NNP /_NN N_NNP
          >_NN 2_CD ._. 0_CD on_IN each_DT of_IN the_DT arrays_NNS using_VBG the_DT amplification_NN
          protocol_NN ._. We_PRP found_VBD that_IN 95_CD %_NN to_TO 100_CD %_NN of_IN the_DT genes_NNS that_WDT are_VBP
          consistently_RB found_VBN to_TO be_VB expressed_VBN using_VBG the_DT regular_JJ
          protocol_NN were_VBD also_RB found_VBN to_TO be_VB expressed_VBN using_VBG the_DT
          amplification_NN protocol_NN ._. For_IN U_NNP 251_CD on_IN four_CD amplified_VBN
          arrays_NNS ,_, the_DT percentages_NNS are_VBP 100_CD %_NN ,_, 99_CD %_NN ,_, 98_CD %_NN ,_, and_CC 100_CD %_NN ;_: for_IN
          LN_NNP 229_CD ,_, 100_CD %_NN ,_, 96_CD %_NN ,_, 95_CD %_NN ,_, and_CC 98_CD %_NN ._.
        
        
          Confirmation_NNP of_IN the_DT results_NNS from_IN amplification_NN
          experiments_NNS
          A_DT key_JJ criterion_NN for_IN the_DT validity_NN of_IN microarray_NN
          experiments_NNS is_VBZ whether_IN the_DT results_NNS are_VBP real_JJ and_CC can_MD be_VB
          confirmed_VBN by_IN other_JJ approaches_NNS ._. In_IN order_NN to_TO obtain_VB
          representative_NN information_NN rather_RB than_IN noise_NN from_IN
          nonspecific_JJ binding_JJ of_IN targets_NNS to_TO the_DT DNA_NNP probes_NNS in_IN a_DT
          microarray_NN experiment_NN ,_, the_DT hybridization_NN has_VBZ to_TO be_VB
          specific_JJ ._. To_TO demonstrate_VB the_DT hybridization_NN specificity_NN in_IN
          our_PRP$ microarray_NN experiments_NNS ,_, we_PRP selectively_RB labeled_VBD a_DT
          specific_JJ target_NN such_JJ as_IN actin_NN or_CC GAPDH_NNP with_IN one_CD dye_NN and_CC
          hybridized_JJ to_TO the_DT microarray_NN ._. Our_PRP$ results_NNS showed_VBD that_IN the_DT
          specific_JJ target_NN only_RB hybridized_JJ to_TO its_PRP$ corresponding_JJ
          spots_NNS on_IN the_DT array_NN [_NN 19_CD ]_NN ._. Second_JJ ,_, in_IN order_NN to_TO confirm_VB
          the_DT results_NNS ,_, the_DT clones_NNS printed_VBN on_IN the_DT microarray_NN have_VBP to_TO
          be_VB correct_JJ and_CC error_NN free_JJ ._. This_DT is_VBZ an_DT important_JJ issue_NN
          because_IN most_JJS clone_NN libraries_NNS used_VBN for_IN making_VBG microarrays_NNS
          contain_VBP significant_JJ errors_NNS ._. To_TO surmount_NN this_DT problem_NN ,_, all_PDT
          the_DT clones_NNS printed_VBN on_IN our_PRP$ microarrays_NNS were_VBD sequence_NN
          verified_VBN before_IN printing_VBG [_NN 20_CD ]_NN ._. Because_IN of_IN those_DT
          quality_NN control_NN measures_NNS ,_, we_PRP expected_VBD that_IN our_PRP$ microarray_NN
          results_NNS should_MD be_VB confirmed_VBN as_RB long_RB as_IN the_DT amplification_NN
          is_VBZ stable_JJ and_CC consistent_JJ among_IN different_JJ experiments_NNS ._.
          From_IN the_DT results_NNS of_IN comparison_NN between_IN U_NNP 251_CD and_CC LN_NNP 229_CD ,_,
          we_PRP selected_VBD six_CD genes_NNS that_WDT showed_VBD differential_NN expression_NN
          either_CC using_VBG both_DT the_DT regular_JJ and_CC the_DT amplification_NN
          procedures_NNS or_CC only_RB using_VBG the_DT amplification_NN procedure_NN ._.
          Among_IN these_DT ,_, four_CD genes_NNS were_VBD detected_VBN by_IN both_DT protocols_NNS
          and_CC two_CD genes_NNS were_VBD only_RB detected_VBN by_IN the_DT amplification_NN
          protocol_NN (_( Figure_NN 1_LS )_) ._. Genes_NNP that_WDT belong_VBP to_TO the_DT latter_JJ case_NN
          are_VBP most_RBS likely_RB expressed_VBD at_IN very_RB low_JJ levels_NNS that_WDT fall_NN
          below_IN the_DT threshold_NN of_IN detection_NN by_IN the_DT regular_JJ protocol_NN ._.
          These_DT genes_NNS were_VBD then_RB tested_VBN by_IN other_JJ molecular_JJ
          methodologies_NNS ._.
          We_PRP first_RB selected_VBN two_CD genes_NNS ,_, S_NNP 100_CD and_CC GFAP_NNP ,_, that_WDT are_VBP
          common_JJ markers_NNS for_IN glial_NN cells_NNS ._. Among_IN U_NNP 251_CD and_CC LN_NNP 229_CD
          cells_NNS ,_, the_DT microarray_NN results_NNS from_IN both_DT protocols_NNS showed_VBD
          that_IN S_NNP 100_CD was_VBD expressed_VBN at_IN higher_JJR levels_NNS in_IN LN_NNP 229_CD cells_NNS
          and_CC GFAP_NNP at_IN higher_JJR levels_NNS in_IN U_NNP 251_CD cells_NNS ._. U_NNP 251_CD and_CC LN_NNP 229_CD
          cells_NNS were_VBD embedded_VBN in_IN paraffin_NN blocks_NNS and_CC sectioned_JJ ._. The_DT
          sections_NNS were_VBD stained_JJ with_IN antibodies_NNS for_IN those_DT two_CD
          antigens_NNS ._. The_DT immunohistochemistry_NN results_NNS showed_VBD that_IN
          S_NNP 100_CD is_VBZ expressed_VBN at_IN higher_JJR levels_NNS in_IN LN_NNP 229_CD cells_NNS and_CC
          GFAP_NNP at_IN higher_JJR levels_NNS in_IN U_NNP 251_CD cells_NNS (_( Fig_NNP 2_CD A_DT )_) ._. Two_CD
          additional_JJ genes_NNS ,_, HLA-DR_NNP alpha_NN and_CC SNRP-B_NNP ,_, that_WDT were_VBD also_RB
          obtained_VBN using_VBG the_DT two_CD protocols_NNS ,_, were_VBD confirmed_VBN by_IN
          northern_JJ blotting_VBG (_( Fig_NNP 2_CD A_DT )_) ._.
          We_PRP mentioned_VBD that_IN some_DT low-expressing_JJ genes_NNS could_MD only_RB
          be_VB detected_VBN by_IN the_DT amplification_NN protocol_NN and_CC not_RB by_IN the_DT
          regular_JJ protocol_NN ._. To_TO confirm_VB whether_IN the_DT new_JJ information_NN
          by_IN this_DT approach_NN is_VBZ reliable_JJ ,_, we_PRP randomly_RB picked_VBD up_RP two_CD
          differentially_RB expressed_VBD genes_NNS ,_, IGFBP_NNP 2_CD and_CC integrin_NN beta_NN
          4_CD ,_, that_WDT were_VBD identified_VBN by_IN the_DT amplification_NN protocol_NN but_CC
          not_RB by_IN the_DT regular_JJ protocol_NN for_IN confirmation_NN using_VBG
          western_JJ blotting_VBG ,_, northern_JJ blotting_VBG and_CC
          immunohistochemistry_NN assays_NNS ._. The_DT results_NNS from_IN these_DT
          experiments_NNS showed_VBD that_IN all_PDT the_DT two_CD genes_NNS were_VBD expressed_VBN
          at_IN higher_JJR levels_NNS in_IN U_NNP 251_CD cells_NNS (_( Figure_NN 2_CD B_NNP )_) as_IN obtained_VBN by_IN
          the_DT microarray_NN data_NN ._. It_PRP should_MD be_VB noted_VBN that_IN for_IN the_DT low_RB
          expressed_VBD genes_NNS that_WDT could_MD only_RB be_VB detected_VBN by_IN the_DT
          amplification_NN protocol_NN ,_, longer_JJR exposure_NN time_NN for_IN the_DT
          northern_JJ blotting_VBG is_VBZ needed_VBN and_CC the_DT signal_NN intensity_NN is_VBZ
          much_RB lower_JJR than_IN that_DT generated_VBD from_IN the_DT high_RB expressed_VBD
          genes_NNS that_WDT could_MD be_VB detected_VBN by_IN both_DT protocols_NNS (_( Figure_NN
          2_CD B_NNP )_) ._.
          In_IN summary_NN ,_, we_PRP have_VBP carried_VBN out_RP a_DT series_NN of_IN
          confirmation_NN experiments_NNS using_VBG northern_JJ blotting_VBG ,_, western_JJ
          blotting_VBG and_CC immunohistochemistry_NN assay_NN and_CC all_DT six_CD
          differentially_RB expressed_VBD genes_NNS revealed_VBD from_IN the_DT
          microarray_NN experiments_NNS have_VBP been_VBN confirmed_VBN ._.
        
      
      
        Discussion_NNP
        A_DT major_JJ difficulty_NN in_IN the_DT study_NN of_IN cancer_NN is_VBZ that_IN cancer_NN
        cells_NNS are_VBP extremely_RB elusive_JJ and_CC the_DT genetic_JJ mutation_NN events_NNS
        are_VBP continuously_RB occurring_VBG temporally_RB and_CC spatially_RB ._. The_DT
        development_NN of_IN high_JJ throughput_NN genomic_JJ technologies_NNS enables_VBZ
        us_PRP to_TO screen_VB thousands_NNS of_IN genes_NNS simultaneously_RB for_IN the_DT
        informative_JJ genes_NNS ,_, yet_RB the_DT power_NN of_IN these_DT technologies_NNS is_VBZ
        greatly_RB attenuated_JJ when_WRB inappropriate_JJ samples_NNS are_VBP studied_VBN ._.
        Generally_RB speaking_VBG ,_, the_DT most_RBS biologically_RB appropriate_JJ
        materials_NNS obtained_VBN from_IN clinical_JJ samples_NNS are_VBP small_JJ in_IN
        quantity_NN ._. This_DT observation_NN motivates_NNS the_DT development_NN of_IN
        experimental_JJ protocols_NNS that_WDT allow_VBP application_NN of_IN genomic_JJ
        technologies_NNS to_TO minute_NN amounts_NNS of_IN biological_JJ materials_NNS ._. In_IN
        this_DT manuscript_NN ,_, we_PRP have_VBP described_VBN such_JJ a_DT method_NN that_WDT
        allows_VBZ us_PRP to_TO use_VB cDNA_NN microarrays_NNS with_IN only_RB 1_CD microgram_NN of_IN
        total_JJ RNA_NNP ._.
        The_DT initial_JJ evaluation_NN of_IN the_DT methodology_NN is_VBZ based_VBN on_IN
        the_DT detection_NN of_IN fluorescent_NN signals_NNS on_IN the_DT microarray_NN
        after_IN hybridization_NN ._. Although_IN we_PRP could_MD see_VB bright_JJ spots_NNS
        with_IN the_DT amplification_NN protocols_NNS ,_, this_DT apparent_JJ "_'' success_NN "_''
        does_VBZ not_RB mean_VB the_DT information_NN so_RB acquired_VBD is_VBZ reliable_JJ ._.
        False_NNP positives_NNS are_VBP often_RB the_DT result_NN of_IN side-effects_JJ during_IN
        amplification_NN ._. We_PRP set_VBD out_IN to_TO assess_VB the_DT accuracy_NN and_CC
        reliability_NN using_VBG both_DT statistical_JJ and_CC experimental_JJ
        approaches_NNS ._. Both_DT approaches_NNS supported_VBD the_DT validity_NN of_IN our_PRP$
        protocol_NN in_IN the_DT identification_NN of_IN differentially_RB expressed_VBD
        genes_NNS in_IN two_CD cell_NN populations_NNS ._. This_DT demonstrates_VBZ that_IN the_DT
        same_JJ genes_NNS are_VBP amplified_VBN to_TO the_DT same_JJ extent_NN in_IN different_JJ
        cell_NN populations_NNS ._. However_RB ,_, in_IN our_PRP$ results_NNS ,_, the_DT amount_NN of_IN
        amplification_NN varies_VBZ from_IN gene_NN to_TO gene_NN ._. Therefore_RB ,_, the_DT
        amplification_NN process_NN is_VBZ not_RB balanced_JJ and_CC changes_VBZ the_DT
        relative_JJ transcript_NN levels_NNS in_IN a_DT given_VBN cell_NN population_NN ._.
        Thus_RB ,_, from_IN the_DT amplified_VBN results_NNS ,_, one_CD cannot_NN infer_NN the_DT
        relative_JJ expression_NN levels_NNS of_IN different_JJ genes_NNS in_IN a_DT single_JJ
        sample_NN ._. However_RB ,_, in_IN most_JJS biological_JJ studies_NNS ,_, identification_NN
        of_IN differentially_RB expressed_VBD genes_NNS among_IN different_JJ samples_NNS
        is_VBZ the_DT main_JJ aim_NN ._. These_DT genes_NNS can_MD serve_VB as_IN useful_JJ markers_NNS
        for_IN diagnosis_NN ,_, for_IN prediction_NN of_IN therapeutic_JJ response_NN ,_, and_CC
        perhaps_RB as_IN a_DT target_NN for_IN developing_VBG new_JJ drugs_NNS ._. Thus_RB ,_, we_PRP have_VBP
        developed_VBN an_DT assay_NN that_WDT will_MD enable_VB us_PRP to_TO approach_VB a_DT series_NN
        of_IN important_JJ clinical_JJ issues_NNS given_VBN a_DT limited_JJ amount_NN of_IN
        material_NN ._. This_DT assay_NN has_VBZ been_VBN used_VBN in_IN several_JJ ongoing_JJ
        studies_NNS and_CC useful_JJ information_NN has_VBZ been_VBN obtained_VBN ._.
      
      
        Conclusion_NNP
        We_PRP have_VBP confirmed_VBN a_DT powerful_JJ and_CC consistent_JJ cDNA_NN
        microarray_NN procedure_NN that_WDT can_MD be_VB used_VBN to_TO study_VB minute_NN
        amounts_NNS of_IN biological_JJ tissue_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Microarray_NNP production_NN
          A_DT total_NN of_IN 2_CD ,_, 304_CD known_VBN human_JJ cDNAs_NNS were_VBD prepared_VBN by_IN
          PCR_NNP from_IN the_DT Research_NNP Genetics_NNP cDNA_NN clone_NN library_NN using_VBG
          the_DT two_CD primers_NNS on_IN the_DT vector_NN ._. The_DT sequences_NNS of_IN the_DT two_CD
          primers_NNS are_VBP :_: up-stream_JJ 5_CD '_POS -_: CTGCAAGGCATTAAGTTGGGTAAC-_NNP 3_CD '_POS ;_:
          down-stream_JJ ,_, 5_CD '_POS -_: GTGAGCGGATAACAATTTCACACAGGAAACAGC-_NNP 3_CD '_'' ._.
          The_DT PCR_NNP products_NNS were_VBD purified_JJ using_VBG MultiScreen_NNP PCR_NNP
          plates_NNS (_( Millipore_NNP Corp_NNP ._. ,_, Bedford_NNP ,_, MA_NNP )_) and_CC verified_VBN by_IN
          sequencing_VBG at_IN our_PRP$ Cancer_NNP Genomics_NNP Core_NNP Lab_NNP prior_RB to_TO
          printing_NN ._. The_DT DNA_NNP clones_NNS ,_, in_IN 394_CD -_: well_RB plates_NNS ,_, were_VBD
          spotted_VBN onto_IN poly-_NN L-_NNP lysine-coated_JJ microscope_NN slides_NNS using_VBG
          a_DT robotic_JJ arrayer_NN (_( Genomic_NNP Solutions_NNPS ,_, Ann_NNP Arbor_NNP ,_,
          Michigan_NNP )_) ._. All_DT the_DT clones_NNS except_IN for_IN the_DT control_NN genes_NNS
          such_JJ as_IN GAPDH_NNP ,_, β-actin_JJ ,_, tubulin_NN and_CC an_DT EST_NNP highly_RB similar_JJ
          to_TO GAPDH_NNP ,_, are_VBP duplicated_VBN on_IN the_DT array_NN ._. After_IN printing_NN ,_,
          the_DT slides_NNS are_VBP dried_VBN ,_, cross-linked_JJ by_IN UV_NNP (_( 650_CD J_NNP /_NN cm_NN 2_LS )_) ,_,
          washed_VBN by_IN water_NN ,_, and_CC stored_VBD dry_JJ ._.
        
        
          RNA_NNP amplification_NN and_CC target_NN labeling_VBG
          U_NNP 251_CD and_CC LN_NNP 229_CD human_JJ glioma_NN cell_NN lines_NNS were_VBD maintained_VBN
          in_IN DMEM_NNP supplemented_JJ with_IN 10_CD %_NN fetal_JJ calf_NN serum_NN
          (_( Gibco-_NNP BRL_NNP ,_, Gaithersburg_NNP ,_, MD_NNP )_) ._. Total_NNP RNA_NNP was_VBD isolated_VBN
          using_VBG TRI_NNP reagent_NN (_( MRC_NNP ,_, Cincinnati_NNP ,_, OH_NNP )_) ._.
          5_LS -_: Amino-propargyl-_NNP 2_CD '_POS -_: deoxycytidine_NN 5_CD '_POS -_: triphosphate_NN
          coupled_VBN to_TO Cy_NNP 3_CD (_( Cy_NNP 5_LS )_) fluorescent_NN dye_NN -_: Cy_NNP 3_CD -_: AP_NNP 3_CD -_: dCTP_NN or_CC
          Cy_NNP 5_CD -_: AP_NNP 3_CD -_: dCTP_NN (_( Cy_NNP 3_CD and_CC Cy_NNP 5_LS )_) were_VBD purchased_VBN from_IN Amersham_NNP
          Pharmacia_NNP Biotech_NNP Inc_NNP ._. (_( Piscataway_NNP ,_, NJ_NNP )_) ._. Reverse_VBP
          transcription_NN was_VBD carried_VBN out_IN in_IN a_DT 20_CD μl_NN volume_NN
          containing_VBG 1_CD μg_NN total_JJ RNA_NNP ,_, 1_CD μg_NN oligdT_NN 25_CD -_: T_NN 7_CD
          (_( 5_CD '_POS -_: AAACGACGGCCAGTGAATTGTAATACGACTCACTATAGGG_NNP -_: CGATT-_NNP 3_CD '_POS )_)
          primer_NN ,_, 1_CD μg_NN template_NN switch_NN primer_NN
          (_( 5_CD '_POS -_: AAGCAGTGGTAACAACGC_NNP -_: AGGGACCGGG-_NNP 3_CD '_POS )_) ,_, 4_CD μl_NN first-strand_JJ
          reaction_NN buffer_NN ,_, 2_CD μl_NN 10_CD mM_NN dithiothreitol_NN (_( DTT_NNP ;_:
          Gibco-_NNP BRL_NNP )_) 1_CD μl_NN 10_CD mM_NN dNTPs_NNS ,_, 1_CD μl_NN SUPERase-in_NNP ,_, (_( Amtion_NNP ,_,
          Austin_NNP ,_, TX_NNP )_) and_CC 200_CD u_NN Superscript_NNP II_NNP reverse_VB
          transcriptase_NN (_( Gibco-_NNP BRL_NNP )_) ._. cDNA_NN synthesis_NN was_VBD completed_VBN
          at_IN 42_CD °_NN C_NNP for_IN 2_CD hours_NNS ._. Then_RB 1_CD u_NN RNase_NNP H_NNP (_( Roche_NNP ,_, Branchburg_NNP ,_,
          NJ_NNP )_) was_VBD added_VBN to_TO the_DT reaction_NN followed_VBN by_IN incubation_NN at_IN
          37_CD °_NN C_NNP for_IN 15_CD min_NN ._. Full-length_NNP ds-c_JJ DNA_NNP was_VBD synthesized_JJ by_IN
          adding_VBG 57_CD μl_NN nuclease-free_JJ water_NN ,_, 10_CD μl_NN 10_CD ×_NN PCR_NNP buffer_NN
          (_( Roche_NNP )_) ,_, 10_CD μl_NN 25_CD mM_NN MgCl_NNP 
          2_CD ,_, 1_CD μl_NN 10_CD mM_NN dNTP_NN and_CC 5_CD u_NN Ampli-_NNP Taq_NNP
          Gold_NNP DNA_NNP Polymerase_NNP (_( Roche_NNP )_) ._. The_DT reaction_NN was_VBD carried_VBN out_RB
          at_IN 95_CD °_NN C_NNP for_IN 10_CD min_NN and_CC then_RB 1_CD or_CC 3_CD cycles_NNS at_IN :_: 95_CD °_NN C_NNP for_IN 1_CD
          min_NN ._. ,_, 65_CD °_NN C_NNP for_IN 6_CD min_NN ._. A_DT prolonged_JJ elongation_NN time_NN up_IN to_TO
          12_CD min_NN was_VBD used_VBN in_IN the_DT final_JJ cycle_NN ._. The_DT PCR_NNP product_NN was_VBD
          purified_JJ by_IN QIAquick_NNP PCR_NNP Purification_NNP Kit_NNP (_( Qiagen_NNP ,_,
          Valencia_NNP ,_, CA_NNP )_) ._. The_DT anti-sense_JJ RNA_NNP (_( aRNA_NN )_) amplification_NN by_IN
          T_NN 7_CD in_IN vitro_NN transcription_NN was_VBD carried_VBN out_IN using_VBG
          MEGAscript_NNP T_NN 7_CD Kit_NNP (_( Ambion_NNP Inc_NNP ._. ,_, Austin_NNP ,_, TX_NNP )_) following_VBG the_DT
          manufacturer_NN 's_POS instructions_NNS ._. After_IN RNA_NNP amplification_NN ,_, the_DT
          DNA_NNP template_NN was_VBD removed_VBN by_IN incubation_NN of_IN the_DT reaction_NN
          with_IN 4_CD units_NNS of_IN RNase-free_NNP DNase_NNP I_PRP (_( Ambion_NNP )_) at_IN 37_CD °_NN C_NNP for_IN
          15_CD min_NN ._. aRNA_NN purification_NN was_VBD achieved_VBN by_IN Rneasy_NNP Mini_NNP Kit_NNP
          (_( Qiagen_NNP )_) ._. The_DT purified_JJ 5_CD μg_NN aRNA_NN was_VBD labeled_VBN with_IN Cy_NNP 3_CD or_CC
          Cy_NNP 5_CD by_IN reverse_NN transcription_NN in_IN a_DT solution_NN containing_VBG 10_CD
          μg_NN of_IN random_JJ hexamer_NN ,_, 4_CD μl_NN first-strand_JJ reaction_NN buffer_NN ,_,
          2_CD μl_NN 10_CD mM_NN dithiothreitol_NN (_( DTT_NNP ;_: Gibco-_NNP BRL_NNP )_) ,_, 1_CD μl_NN of_IN 2_CD mM_NN
          dATP_NN ,_, dGTP_NN ,_, dTTP_NN and_CC 1_CD mM_NN dCTP_NN ,_, 1_CD μl_NN SUPERase-in_NNP ,_,
          (_( Amtion_NNP )_) and_CC 200_CD u_NN Superscript_NNP II_NNP reverse_VB transcriptase_NN
          (_( Gibco-_NNP BRL_NNP )_) ._. The_DT labeling_VBG was_VBD completed_VBN at_IN 42_CD °_NN C_NNP for_IN 2_CD
          hours_NNS ._. Then_RB the_DT labeled_VBN cDNA_NN was_VBD purified_JJ using_VBG MicroSpin_NNP
          G-_NNP 50_CD columns_NNS (_( Amersham_NNP Pharmacia_NNP )_) ._. The_DT volume_NN was_VBD reduced_VBN
          to_TO about_IN 10_CD μl_NN using_VBG a_DT Speed-_NNP Vac_NNP system_NN (_( ThermoSavant_NNP ,_,
          AES_NNP 2010_CD )_) before_IN hybridization_NN ._.
        
        
          Microarray_NNP hybridization_NN and_CC scanning_VBG
          To_TO hybridize_NN the_DT arrays_NNS ,_, purified_JJ and_CC labeled_VBN cDNA_NN
          targets_NNS were_VBD dissolved_VBN in_IN 100_CD μl_NN total_JJ volume_NN of_IN
          ExpressHyb_NNP solution_NN (_( Clontech_NNP ,_, Palo_NNP Alto_NNP ,_, CA_NNP )_) containing_VBG
          8_CD μg_NN of_IN polydA_NN 
          40_CD -_: 60_CD (_( Amersham_NNP Pharmacia_NNP )_) ,_, 2_CD μg_NN of_IN
          yeast_NN tRNA_NN (_( Gibco-_NNP BRL_NNP )_) ,_, 10_CD μg_NN of_IN human_JJ Cot_NNP I_PRP DNA_NNP
          (_( Gibco-_NNP BRL_NNP )_) ._. The_DT mixture_NN was_VBD heated_VBN to_TO 95_CD °_NN C_NNP for_IN 10_CD min_NN ,_,
          then_RB applied_VBN to_TO the_DT slides_NNS and_CC covered_VBN by_IN a_DT coverslip_NN ._.
          Hybridization_NNP was_VBD carried_VBN out_RB at_IN 60_CD °_NN C_NNP for_IN 14_CD -_: 16_CD hours_NNS in_IN
          a_DT moisturized_JJ box_NN in_IN an_DT incubator_NN ._. Slides_NNS were_VBD washed_VBN at_IN
          37_CD °_NN C_NNP in_IN 1_CD ×_NN SSC_NNP (_( 3_CD M_NNP sodium_NN chloride_NN ,_, 0_CD ._. 3_CD M_NNP sodium_NN
          citrate_NN )_) ,_, 0_CD ._. 01_CD %_NN SDS_NNP ,_, 0_CD ._. 2_CD ×_NN SSC_NNP ,_, 0_CD ._. 01_CD %_NN SDS_NNP ,_, and_CC twice_RB in_IN
          0_CD ._. 1_CD ×_NN SSC_NNP sequentially_RB for_IN 2_CD min_NN each_DT ._. Hybridized_NNP arrays_NNS
          were_VBD scanned_JJ at_IN 10_CD -_: μm_NN resolution_NN on_IN a_DT LSIV_NNP scanner_NN
          (_( Genomic_NNP Solution_NN ,_, Ann_NNP Arbor_NNP ,_, MI_NNP )_) ._.
        
        
          Data_NNP quantification_NN
          Scanned_NNP microarray_NN images_NNS (_( 16_CD -_: bit_NN TIFF_NNP formatted_JJ
          files_NNS )_) were_VBD quantified_VBN with_IN ArrayVision_NNP ™_NN (_( Imaging_NNP
          Research_NNP ,_, Inc_NNP ._. ,_, St_NNP ._. Catherine_NNP 's_POS ,_, Ontario_NNP ,_, Canada_NNP )_) ,_, and_CC
          values_NNS were_VBD recorded_VBN for_IN spot_NN intensity_NN ,_, local_JJ background_NN
          intensity_NN ,_, and_CC signal-to-noise_JJ (_( S_NNP /_NN N_NNP )_) ratio_NN ._. Spot_NNP
          intensity_NN was_VBD computed_JJ as_IN the_DT integrated_VBN optical_JJ density_NN
          or_CC volume_NN in_IN a_DT fixed-size_JJ circle_NN ;_: background_NN intensity_NN
          was_VBD computed_JJ as_IN the_DT median_JJ pixel_NN value_NN of_IN four_CD
          diamond-shaped_JJ regions_NNS at_IN the_DT corners_NNS of_IN each_DT spot_NN ._.
          Background-corrected_NNP intensity_NN was_VBD computed_JJ by_IN
          subtracting_VBG local_JJ background_NN from_IN spot_NN intensity_NN ._. The_DT S_NNP /_NN N_NNP
          ratio_NN was_VBD computed_JJ by_IN dividing_VBG the_DT background-corrected_JJ
          intensity_NN by_IN the_DT standard_JJ deviation_NN (_( SD_NNP )_) of_IN the_DT
          background_NN pixels_NNS ._.
        
        
          Data_NNP normalization_NN
          Data_NNS from_IN all_DT microarrays_NNS was_VBD imported_VBN into_IN S-_NNP plus_CC ™_NN
          (_( Insightful_NNP Corp_NNP ._. ,_, Seattle_NNP ,_, WA_NNP )_) ,_, for_IN further_JJ analysis_NN ._.
          For_IN each_DT microarray_NN ,_, the_DT background-corrected_JJ spot_NN
          intensities_NNS were_VBD normalized_JJ by_IN setting_VBG the_DT 75_CD th_NN
          percentile_NN equal_JJ to_TO 1000_CD ._. This_DT procedure_NN brings_VBZ the_DT
          median_JJ log_NN ratio_NN between_IN channels_NNS close_RB to_TO 1_CD for_IN
          expressed_VBD spots_NNS ,_, and_CC it_PRP also_RB permits_VBZ us_PRP to_TO compare_VB
          individual_JJ channels_NNS across_IN arrays_NNS ._. After_IN normalization_NN ,_,
          any_DT spot_NN whose_WP$ normalized_JJ intensity_NN remained_VBD below_IN the_DT
          threshold_NN value_NN of_IN 150_CD was_VBD considered_VBN to_TO be_VB undetectable_JJ ,_,
          and_CC its_PRP$ value_NN was_VBD replaced_VBN by_IN the_DT threshold_NN value_NN ._. In_IN our_PRP$
          arrays_NNS ,_, a_DT normalized_JJ value_NN of_IN 150_CD corresponds_NNS roughly_RB to_TO
          a_DT spot_NN whose_WP$ S_NNP /_NN N_NNP ratio_NN equals_VBZ 1_CD ,_, and_CC thus_RB any_DT spot_NN whose_WP$
          background-corrected_JJ intensity_NN falls_VBZ below_IN this_DT threshold_NN
          cannot_NN be_VB reliably_RB distinguished_VBN from_IN background_NN noise_NN ._.
          Finally_RB the_DT background-corrected_JJ ,_, normalized_JJ signal_NN
          intensities_NNS were_VBD log-transformed_JJ (_( base_NN two_CD )_) for_IN further_JJ
          analysis_NN ._.
        
        
          Northern_NNP blotting_VBG analysis_NN
          The_DT sequencing_VBG verified_VBN cDNAs_NNS used_VBN to_TO print_VB the_DT
          microarrays_NNS were_VBD used_VBN as_IN templates_NNS and_CC the_DT probes_NNS were_VBD
          labeled_VBN using_VBG Rediprime_NNP II_NNP Random_NNP Prime_NNP Labeling_VBG System_NNP
          (_( Amersham_NNP )_) ._. For_IN northern_JJ blotting_VBG ,_, 20_CD μg_NN of_IN total_JJ RNA_NNP was_VBD
          electrophorized_JJ on_IN a_DT denaturing_VBG agarose_NN gel_NN ,_, transferred_VBN
          to_TO nylon_NN membrane_NN ,_, and_CC hybridized_JJ to_TO 33_CD P_NN labeled_VBD cDNA_NN
          probes_NNS as_IN described_VBN previously_RB [_NN 11_CD ]_NN ._.
        
        
          Western_NNP blotting_VBG analysis_NN
          For_IN western_JJ blotting_VBG ,_, 40_CD μg_NN of_IN total_JJ cellular_JJ protein_NN
          was_VBD run_VBN on_IN a_DT SDS-PAGE_NNP gel_NN ,_, transferred_VBN to_TO a_DT nylon_NN
          membrane_NN ,_, and_CC incubated_JJ with_IN IGFBP_NNP 2_CD antibody_NN (_( Santa_NNP Cruz_NNP
          Biotechnology_NNP ,_, Inc_NNP ._. )_) following_VBG the_DT procedure_NN as_IN described_VBN
          [_NN 11_CD ]_NN ._.
        
        
          Immunohistochemistry_NNP assay_NN
          Cell_NNP pellets_NNS were_VBD first_RB embedded_VBN to_TO paraffin_NN block_NN and_CC
          sections_NNS cut_NN and_CC mounted_VBD onto_IN microscope_NN slides_NNS ._. The_DT
          presence_NN of_IN S_NNP 100_CD ,_, GFAP_NNP ,_, and_CC IGFBP_NNP 2_CD antigens_NNS was_VBD detected_VBN
          by_IN their_PRP$ antibodies_NNS following_VBG standard_JJ
          immunohistochemistry_NN procedures_NNS [_NN 11_CD ]_NN ._.
        
      
    
  
